Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited has presented new data on its novel drug candidate, SOF-SKN, at the Australian Rheumatology Association’s Annual Scientific Meeting. This marks the company’s first engagement with a specialist rheumatology audience. SOF-SKN, designed to treat autoimmune diseases like cutaneous lupus erythematosus, demonstrated significant reduction in inflammation in a rheumatology-relevant animal model. The upcoming HERACLES clinical trial will further evaluate its efficacy. This development underscores Noxopharm’s commitment to addressing the growing autoimmune disease market and enhancing its industry positioning.
More about Noxopharm Ltd.
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company is pioneering technology to enhance a wide range of mRNA medicines and is targeting autoimmune diseases with its Sofra technology platform.
YTD Price Performance: -19.35%
Average Trading Volume: 83,002
Technical Sentiment Signal: Buy
Current Market Cap: A$21.92M
See more insights into NOX stock on TipRanks’ Stock Analysis page.